Erythrosedimentation Rate Research Articles

Intervertebral discitis in children

Twelve children with lumbar discitis were reviewed. The average age at diagnosis was 2.5 years. Seven were girls, and the follow-up varied between 2 and 10 years (average 5 years). The clinical signs were general irritability, abdominal or hip pain and refusal to walk or to sit. The erythrosedimentation rate was elevated in all but two. Radiographic narrowing of the disc space was seen in seven patients. Needle disc aspiration was done in five cases with two being positive for Staphylococcus aureus. Blood culture was positive in one case. Magnetic resonance imaging helped to diagnose the condition in three. Treatment consisted of bed rest and immobilisation of the spine; intravenous antibiotics were given to nine children. The natural course of the disease was benign in all our twelve cases.

Alimentación enteral precoz en lactantes con infección respiratoria baja

A decrease in food intake during the acute phase of lower respiratory tract infections may affect the course of illness. To determine if enteral feeding improves the clinical course of lower respiratory infections (LRI) we studied 42 infants (2 to 12 months of age) with LRI which were given antibiotics and salbutamol therapy based on clinical and X-ray findings. On admission to the hospital patients were randomly allocated to group A (fed by nasogastric tube as intermittent bolus); group B (infants fed by continuous drip via nasogastric tube) and group C (subjects fed ad-libitum by the oral route). Feedings consisted of powdered whole cow's milk formula, reconstituted to 7.5% (W/V), with added sucrose 5% and maltodextrin 5% (77 kcal/dl). Energy intake in group A increased from 69 to 110 kcal.kg.day; in group B, from 68 to 114 kcal.kg.day, and in group C, from 55 to 109 kcal.kg.day (ANOVA, p < 0.005 for the first three days). Infants of groups A and B had shorter hospital stays than C (8.7 and 8.4 vs. 9.8 days, ANOVA, p < 0.02) and a faster improvement of respiratory failure index (4.1 and 3.8 vs. 5.5. days, p < 0.001). Groups A and B also showed greater decrease in their heart rates (mean 170 down to 134 beats/min) than group C patients (169 down to 142 beats/min), p < 0.01 at discharge from the hospital. No differences were noted in trends of respiratory rate, weight/length, albuminemia, C-reactive protein, erythro-sedimentation rate or glycemia. No adverse effects of nasogastric tube feeding were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Recurrent and/or metastatic head and neck squamous cell carcinoma: A clinical, univariate and multivariate analysis of response and survival with cisplatin‐based chemotherapy

One hundred two patients with recurrent and/or metastatic head and neck squamous cell cancer were entered into four consecutive phase II trials, all cisplatinum (C-DDP, 100 mg/m2/cycle)-based. The two combinations tried were C-DDP, bleomycin, and fluorouracil (CFB) on 54 patients, and cisplatinum and vindesin in 36 patients (CV). The CFB combination was given with C-DDP by continuous infusion over 96 hours (23 patients) or on day 1 (31 patients). The CV regimen was also given in two different schedules, with VDS at 3 mg/m2/g weekly (12 patients) or by a 96-hour continuous infusion (0.6 to 1.0 mg/m2/d) in 24 patients. The following variables: sex, age, performance status, previous therapy, local recurrence, length of disease-free interval (DFI), distant metastases, weight loss, primary site, histological differentiation, type of chemotherapy, previous chemotherapy, evaluable/measurable disease, erythrosedimentation rate, and their relation with response to chemotherapy (WHO) and survival were submitted to both univariate and multivariate analysis (Cox). Overall response rate (RR:CR + PR) was 25 (28%) of 90. In the CFB protocols, RR was 12 (22%) of 54 vs. 13 (38%) of 36 (P = 0.15, NS) in the CV combination group. For the four different combinations the RR was CFB C-DDPci 7 (30%) of 23, CFB C-DDP 1 hour 5 (16%) of 31, CV VDS weekly 2 (17%) of 12, CV VDSci 11 (45%) of 24. The patient populations were very different, with the latest combination consisting of metastatic patients exclusively. Univariate analysis of multiple variables showed age less than 60 years, PS:0 or 1, no previous therapy, absence of local relapse, metastatic disease, long DFI, and that measurable disease was significant for the probability of response. Median survival was 7 months for the 90 evaluated patients, 5 months for nonresponders, and 9 months for responders (P = 0.01). In the univariate analysis, significant factors for survival were PS:0 or 1, a weight loss below 10%, long DFI, response to chemotherapy, erythrosedimentation rate (ESR) of less than 30 mm/1st hr, presence of bone metastasis, and the number of metastases. Multivariate analysis shows PS, the absence of local relapse, and disease-free interval as significant prognostic factors for response. Multivariate analysis factors of significance for survival were PS, weight loss, and response to chemotherapy. The analysis of the clinical pattern showed an evolution in RR from 3 (8%) of 36 on previously irradiated local recurrent disease to 8 (73%) of 11 in previously untreated patients with metastatic disease at presentation.(ABSTRACT TRUNCATED AT 400 WORDS)

Proposal of classification and therapeutic criteria of lymphosarcoma and reticulosarcoma

Proposal of classification and therapeutic criteria of lymphosarcoma and reticulosarcoma

PROPOSAL OF CLASSIFICATION AND THERAPY OF HODGKIN'S DISEASE

A new clinical classification for Hodgkin's disease is proposed by the Committee for the Study of Malignant Lymphomas of the National Cancer Institute of Milan in cooperation with the Institute of Radiology of the University of Milan. The method of treatment of Hodgkin's disease adopted in these Institutes is also outlined. The histologic classification includes paragranuloma, nodular sclerosis, granuloma and sarcoma. Stage I: disease limited to a single peripheric lymphatic region. Within this stage two groups can be recognized: a) involvement of one single lymph node or few nodes limited to a small area of the region (unifocal lesions); b) involvement of many nodes spread throughout the region (uniregional lesions). Stage II: disease limited to two contiguous lymphatic regions, or to few deep nodes (mediastinal, retroperitoneal). Stage III: disease limited to two non contiguous peripheric lymphatic regions, or to many peripheric and/or deep (mediastinal, retroperitoneal) regions, provided the involvement is either above or below the diaphragm. Stage IV: generalized disease with involvement of lymph nodes above and below the diaphragm, or involvement of one or more lymphatic regions with concomitant involvement of visceral organs, bones, marrow, nervous system and skin. Systemic symptoms and signs, fatigue, fever, night sweats, loss of weight, itching, anemia, lymphocytopenia, high erythrosedimentation rate) must be recorded in each case to evaluate prognosis and proper treatment, bu are not considered in this classification for lymph node staging. Primary visceral, bone, nervous and cutaneous involvement is exceptional; therefore staging for such lesions is not considered in this classification. In all stages endolymphatic radiotherapy with Lipiodol F 131I is indicated (10 ml in each foot with 2.5 mc/ml, corresponding to a tumor-dose of 15 - 20,000 rads). This is considered as a radical as well as a prophylactic treatment for those lymph nodes adequally filled with the contrast material; in case of non filling or incomplete filling of part of the lymph node chain, treatment will be completed with external radiation therapy. Stage I and II are treated with radical and prophylactic radiotherapy. If systemic symptoms and signs are still present after radiotheraphy, a course with anticancer drugs will be administered. Radiation therapy is given with high voltage or Co60 units. In radical treatments tumor doses of at least 3,000 r within 3–4 weeks are administered to all involved lymphatic regions. Prophylactic radiotherapy is indicated for regions clinically free of disease but contiguous to the involved areas, with tumor doses not less than 3,000 r in 3–4 weeks. In stage II radical radiotherapy follows a course with chemotherapy. In stage IV chemotherapy is the treatment of choice; palliative radiotherapy is given to any bulk of tumors, wherever the location, when specific symptoms can be attributed to the masses. The anticancer drug of choice is methyl-bis-(β-chloro-ethyl)-amine HCl(HN2) 0.4 mg/kg i.v., for those patients who did not receive any previous course of chemotherapy. Otherwise, as well as during the course of the disease, other polyfunctional alkylating agents, vinblastine (alone or in combination with chlorambucil), methylhydrazine, and corticosteroids will be administered according to each clinical situation. Radical surgery followed by radical radiotherapy is reserved for primary lymphatic involvement only in specially selected patients in stage I with unifocal lesions. Primary involvement of the stomach, small bowel or colon is treated by surgical extirpation and radiotherapy. Splenectomy is indicated when this viscus is the only site of involvement. During pregnancy radiation therapy is not administered below the diaphragm. Chemotherapy is not given during the first 4 months of pregnancy. The need for one internationally accepted clinical classification of Hodgkin's disease is stressed.